← Back to Search

ERAS Group for Cancer of the Female Reproductive System (ERAS Trial)

N/A
Waitlist Available
Led By Shireen Ahmad, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

ERAS Trial Summary

This study is evaluating whether a new perioperative care plan may help reduce the length of stay for individuals who have surgery for gynecologic cancer.

Eligible Conditions
  • Cancer of the Female Reproductive System

ERAS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total length of hospital stay (days)
Secondary outcome measures
30-day mortality rates
Achievement of Postoperative Milestones
Patient reported satisfaction
+6 more

ERAS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ERAS GroupExperimental Treatment2 Interventions
ERAS (enhanced recovery after surgery)
Group II: No Intervention Conventional StrategyActive Control1 Intervention
Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
No Intervention Conventional Strategy
2016
N/A
~120
ERAS
2018
Completed Phase 4
~2150

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,585 Previous Clinical Trials
917,111 Total Patients Enrolled
Shireen Ahmad, MDPrincipal Investigator - Northwestern University
Northwestern University
2 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

~14 spots leftby Apr 2025